(Hou Jiaxin, a reporter from the People’s Daily Health Client) According to incomplete statistics from the People’s Daily’s health client, a total of 10 companies in the national pharmaceutical health field this week (April 15th-April 19th) have received investment and financing.Among them, Binhui Biological, Shenoluo Medical, and Visual Micro -shaped financing exceeded 100 million yuan.On the whole, financing companies involve innovative biomedicine, cell and gene therapy, neurotoscope medical devices, ophthalmology intelligent diagnosis and treatment equipment.
Biopharmaceutical
Shenzhen Cell Valley: Complete nearly 100 million yuan angel+Pre-A round of capital increase of capital expansion
On April 18, Shenzhen Cell Valley successfully completed nearly 100 million yuan angel+Pre-A round-to-round capital increase.The main purpose of capital increase and share expansion is to expand the company’s business scale and improve the company’s profitability and market competitiveness.
Shenzhen Cell Valley is a one -stop comprehensive outsourcing service provider focusing on the cell and gene therapy industry. It was jointly founded by returnee scientists from Harvard University and the University of California.Shenzhen Cell Valley is a major public service platform in Shenzhen’s biopharmaceutical industry and a key common technology research center of the National Engineering Research Center of the cell industry.
Shenzhen Cell Valley R & D personnel are working.Shenzhen Cell Valley Official Website Map
Xitong Bio: Get seed wheel financing nearly 10 million yuan
On April 18, Xitong Biotechnology Co., Ltd. announced the success of nearly 10 million yuan of seed round financing. The financing was led by Suzhou Shishangbai Venture Partnership.
Xitong Bio is a biomedical tool developer, committed to developing innovative biomedical tools.Founded on July 10, 2023, the company aims to solve the problem of low technical docking between repetitiveness and reliability of the current R & D side and low research results and industrialization.
Binhui Bio: Get hundreds of millions of yuan C financing
On April 17, Binhui Bio completed hundreds of millions of yuan C financing, and investors include Zhongbo Juli.
Binhui Bio is a developer of tumor immunotherapy for solubbuing virus drugs. It was founded by Dr. Liu Binlei, the main member of the original research team who has been approved to be listed on the T-VEC (imlygic).(OH2) injection, this product is suitable for lung cancer, head and neck tumors, lymphoma, liver cancer, melanoma and other diseases. It can also be combined with traditional radio and chemotherapy, which aims to improve the efficacy and reduce side effects for users.
Zun Zun creature: complete nearly 100 million yuan A+round of financing
On April 15th, Zunzun Bio announced the completion of nearly 100 million yuan A+round of financing. This round of financing was jointly led by Tailong Investment and Taiyu Investment.This round of financing will help Zunzun Medicine to accelerate the development and service of innovative biomedicine.
Established in 2017, it is a developer focusing on biomedical fields. It has a variety of cell therapy technology, including CAR-T/TCR-T cell technology, including tumors.The company is committed to providing patients with more effective and secure treatment plans to promote technological innovation in the field of biomedical.
medical instruments
Shenluo Medical: Get hundreds of millions of yuan B+round financing
On April 18, Shenluo Medical announced that it had received hundreds of millions of yuan B+round of financing.The round of financing was led by Obo Capital, and the old shareholder Bo Yuan Capital followed.This round of financing will be mainly used for new product research and development, clinical research, registration application, core technology iterative and commercialization expansion of Shenluo Medical.
As a neural regulatory platform company, Shenluo Medical is committed to the independent research and development and production of medical devices in the field of implantable neuropathic stimulation and brain machine interface, and the goal of continuously providing patients with inclusive neurological regulatory treatment products.
To Qin Instrument: Complete tens of millions of yuan A+ round of financing
On April 15th, the Qin instrument completed tens of millions of yuan A+ round of financing. This round of raised funds will be used to invest in Qin Headquarters, R & D, and production base construction.
Established in the Qin instrument in 2018, based on the independent development system, ion source, quality analyzer, detector and data system as the core, develop small portable and large mass spectrometer products, and is committed to providing customers with comprehensive analysis and testing comprehensive aspectsThe solution continues to help users in the fields of food safety, medical and health and other fields obtain appropriate detection instruments.
Rui Meng Medical: Complete tens of millions of yuan A round of financing
On April 15th, Rui Meng Medical announced the completion of tens of millions of RMB rounds of financing. This round of financing was continued to receive investment by Zijin Port Capital.This financing fund is mainly used to increase investment in R & D and automated production lines.
Rui Meng Medical was established in September 2019. It brings together senior people in the fields of medical devices, health management, mobile Internet, big data processing and other fields to build a new business -based medical device research and development and production enterprise.Wearing, implanted), new medical device Internet of Things products, and intelligent services for professional disease management.
medical service
Xinyi Biological: Complete nearly 100 million yuan B+round of financing
On April 18, Jixin Bio has successfully completed nearly 100 million yuan B+financing jointly invested by Shengdi Investment, Lilly Asia Fund and Jiuzhi Capital, and Xinyi Biological has received 100 million yuan in Beijing Pharmaceutical Fund.It is reported that this round of financing will be used to accelerate the company’s clinical registration of the company’s digital PCR and molecular POCT series reagent products, and promote the company’s high -quality development and new business development.
Beijing Xinyi Biotechnology Co., Ltd. was established in October 2015. It has high -level R & D teams in equipment, chips, materials, reagents, software and other fields.Authoritative journals published academic papers and undertake national scientific research funds.
Seal Code Bio: Complete tens of millions of yuan seed round financing
On April 16, the industry -leading gene editing company’s coded biology completed tens of millions of RMB seed round financing, which was exclusively led by Mi Fang Health Fund.The funds raised in this round of financing will be mainly used for the development and promotion of gene editing pipelines, and the construction of super small editor platforms.
Established in 2023, the code creature is committed to the clinical drug clinical of high -efficiency ultra -small gene editors into a genetic drug that is “administered once and is for life -long healing.”The company has the world’s leading ultra -small high -efficiency gene editor Alphacas, a genetic editor -based mining platform based on the macorn group, and has the engineering ability and rapid target screening and pipeline development capabilities of ultra -small gene editing.
Visual micro -image: Complete over 100 million yuan D round financing
On April 15th, the visual micro -shaped image announced the completion of the D -round financing, and the financing amount exceeded 100 million yuan. The institutions involved in investment include Haitong Kaiyuan.
Founded in Silicon Valley in the United States in 2014.With the support of the national industrial policy in 2015, the company’s headquarters moved to the country, and currently has three major R & D centers in Silicon Valley, Shanghai, and Luoyang.
Report/feedback
